Stock Movers Novo Soars on Wegovy Pill Approval; Huntington Ingalls Rallies; Orsted Declines
Dec 23, 2025
Novo Nordisk's stock skyrocketed after gaining US approval for a pill version of its popular weight loss treatment, Wegovy, set to launch soon. Meanwhile, Huntington Ingalls saw its shares rally thanks to President Trump's announcement of a new battleship class, revitalizing the Navy's fleet amid budget concerns. In contrast, Orsted's stock dipped as the company considers legal action against the US decision to suspend offshore wind farm leases, raising issues about permits and national security.
AI Snips
Chapters
Transcript
Episode notes
Account For Patient Preference
- Consider patient preference when evaluating obesity treatments since many avoid injections.
- A lower-cost oral option may increase adoption among those unwilling to use injectables.
Oral Wegovy Broadens Market Access
- Novo Nordisk's shares jumped after FDA approval for an oral Wegovy pill, broadening its obesity treatment reach.
- The pill launches early January at about $149 a month for the starting dose, offering a lower-price alternative to injections.
Obesity Market Duel Intensifies
- Nathan Hager and Lisa Mateo framed the obesity market as a duopoly between Novo Nordisk and Eli Lilly.
- Novo needed the pill to defend market share after shares had nearly halved year-to-date due to competition.